Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Pfizer Inc. (NYSE:PFE)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Beginner level

Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Long-term Activity Ratios (Summary)

Pfizer Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Net fixed asset turnover 3.01 3.38 3.49 3.61 3.71 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 — — —
Total asset turnover 0.27 0.27 0.28 0.30 0.31 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 — — —
Equity turnover 0.66 0.75 0.76 0.78 0.82 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Pfizer Inc.’s net fixed asset turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Pfizer Inc.’s total asset turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Pfizer Inc.’s equity turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Net Fixed Asset Turnover

Pfizer Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenues 5,948  12,131  11,801  12,028  12,688  12,680  13,264  13,118  13,977  13,298  13,466  12,906  13,703  13,168  12,896  12,779  13,627  13,045  13,147  13,005 
Property, plant and equipment, less accumulated depreciation 13,900  14,403  14,113  14,040  13,967  13,701  13,521  13,467  13,385  14,036  13,919  13,971  13,865  13,505  13,386  13,238  13,318  13,284  13,609  13,584 
Long-term Activity Ratio
Net fixed asset turnover1 3.01 3.38 3.49 3.61 3.71 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 — — —
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 3.83 3.74 3.77 4.06 3.97 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 — — —
AbbVie Inc. 8.73 8.15 7.38 11.50 11.23 11.36 11.33 11.42 11.36 10.91 11.10 10.47 10.07 10.11 10.05 10.04 9.85 — — —
Amgen Inc. 4.96 4.94 4.78 4.68 4.51 4.55 4.58 4.59 4.54 4.51 4.48 4.44 4.37 4.45 4.41 4.41 4.41 — — —
Bristol-Myers Squibb Co. 7.22 6.86 6.03 5.07 4.18 5.00 4.92 4.67 4.49 4.33 4.25 4.16 4.15 4.10 4.09 3.98 3.90 — — —
Eli Lilly & Co. 2.83 2.80 2.88 2.92 2.83 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 — — —
Gilead Sciences Inc. — 4.74 4.70 4.90 4.91 5.03 5.16 5.31 5.41 5.76 6.23 7.11 7.79 8.72 9.31 9.80 10.45 11.48 12.29 13.34
Illumina Inc. 3.51 3.56 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36 — — —
Johnson & Johnson 4.40 4.53 4.57 4.75 4.65 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 — — —
Merck & Co. Inc. 2.67 2.80 2.99 3.15 3.11 3.22 3.20 3.19 3.18 3.27 3.27 3.24 3.23 3.27 3.31 3.32 3.31 — — —
Regeneron Pharmaceuticals Inc. 2.64 2.63 2.64 2.71 2.72 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 — — —
Vertex Pharmaceuticals Inc. 6.47 6.51 7.42 6.55 5.59 4.93 4.72 4.40 3.75 3.50 3.21 3.02 3.15 3.02 2.88 2.85 2.44 — — —
Zoetis Inc. 3.03 3.12 3.15 3.21 3.23 3.39 3.48 3.51 3.51 3.68 3.80 3.75 3.70 3.69 3.70 3.62 3.54 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q4 2020 Calculation
Net fixed asset turnover = (RevenuesQ4 2020 + RevenuesQ3 2020 + RevenuesQ2 2020 + RevenuesQ1 2020) ÷ Property, plant and equipment, less accumulated depreciation
= (5,948 + 12,131 + 11,801 + 12,028) ÷ 13,900 = 3.01

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Pfizer Inc.’s net fixed asset turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Total Asset Turnover

Pfizer Inc., total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenues 5,948  12,131  11,801  12,028  12,688  12,680  13,264  13,118  13,977  13,298  13,466  12,906  13,703  13,168  12,896  12,779  13,627  13,045  13,147  13,005 
Total assets 154,229  178,983  177,934  166,336  167,489  170,446  156,199  155,421  159,422  167,838  164,980  164,612  171,797  172,151  168,558  168,784  171,615  178,430  170,658  162,929 
Long-term Activity Ratio
Total asset turnover1 0.27 0.27 0.28 0.30 0.31 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 — — —
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.48 0.47 0.46 0.48 0.47 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 — — —
AbbVie Inc. 0.30 0.27 0.24 0.37 0.37 0.55 0.57 0.58 0.55 0.49 0.50 0.43 0.40 0.40 0.40 0.40 0.39 — — —
Amgen Inc. 0.39 0.37 0.36 0.37 0.37 0.37 0.38 0.35 0.34 0.33 0.33 0.31 0.27 0.27 0.28 0.28 0.28 — — —
Bristol-Myers Squibb Co. 0.36 0.31 0.27 0.24 0.20 0.42 0.43 0.67 0.64 0.65 0.66 0.64 0.62 0.61 0.61 0.61 0.58 — — —
Eli Lilly & Co. 0.53 0.53 0.55 0.56 0.57 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 — — —
Gilead Sciences Inc. — 0.37 0.39 0.37 0.36 0.37 0.35 0.35 0.34 0.34 0.35 0.37 0.37 0.42 0.47 0.50 0.53 0.55 0.64 0.68
Illumina Inc. 0.43 0.44 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56 — — —
Johnson & Johnson 0.47 0.47 0.51 0.53 0.52 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 — — —
Merck & Co. Inc. 0.52 0.53 0.52 0.57 0.55 0.55 0.53 0.52 0.51 0.49 0.49 0.47 0.46 0.43 0.43 0.41 0.42 — — —
Regeneron Pharmaceuticals Inc. 0.50 0.51 0.55 0.51 0.53 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 — — —
Vertex Pharmaceuticals Inc. 0.53 0.53 0.53 0.54 0.50 0.48 0.49 0.50 0.49 0.61 0.60 0.61 0.70 0.72 0.65 0.69 0.59 — — —
Zoetis Inc. 0.49 0.48 0.49 0.55 0.54 0.55 0.55 0.54 0.54 0.55 0.65 0.63 0.62 0.55 0.64 0.65 0.64 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q4 2020 Calculation
Total asset turnover = (RevenuesQ4 2020 + RevenuesQ3 2020 + RevenuesQ2 2020 + RevenuesQ1 2020) ÷ Total assets
= (5,948 + 12,131 + 11,801 + 12,028) ÷ 154,229 = 0.27

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Pfizer Inc.’s total asset turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Equity Turnover

Pfizer Inc., equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Revenues 5,948  12,131  11,801  12,028  12,688  12,680  13,264  13,118  13,977  13,298  13,466  12,906  13,703  13,168  12,896  12,779  13,627  13,045  13,147  13,005 
Total Pfizer Inc. shareholders’ equity 63,238  65,259  64,336  65,026  63,143  65,103  59,568  58,806  63,407  71,319  69,778  73,184  71,308  60,770  58,368  58,435  59,544  63,306  62,769  63,067 
Long-term Activity Ratio
Equity turnover1 0.66 0.75 0.76 0.78 0.82 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 — — —
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.06 1.03 1.03 1.06 1.03 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 — — —
AbbVie Inc. 3.50 2.66 2.46 — — — — — — — — 8.33 5.54 4.08 4.44 5.25 5.53 — — —
Amgen Inc. 2.58 2.17 2.17 2.41 2.30 2.04 2.07 2.07 1.80 1.54 1.48 1.40 0.86 0.68 0.69 0.71 0.73 — — —
Bristol-Myers Squibb Co. 1.12 0.79 0.71 0.62 0.51 1.37 1.49 1.53 1.61 1.62 1.75 1.64 1.77 1.39 1.38 1.38 1.20 — — —
Eli Lilly & Co. 4.35 4.81 5.61 7.50 8.56 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 — — —
Gilead Sciences Inc. — 1.31 1.21 1.01 0.98 1.07 0.97 1.00 1.01 0.96 1.05 1.18 1.26 1.09 1.24 1.40 1.59 1.85 2.06 2.42
Illumina Inc. 0.69 0.69 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09 — — —
Johnson & Johnson 1.31 1.25 1.28 1.35 1.38 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 — — —
Merck & Co. Inc. 1.90 1.62 1.71 1.83 1.81 1.71 1.61 1.56 1.58 1.29 1.27 1.21 1.17 1.04 1.01 1.00 0.99 — — —
Regeneron Pharmaceuticals Inc. 0.77 0.81 0.88 0.66 0.71 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 — — —
Vertex Pharmaceuticals Inc. 0.71 0.74 0.72 0.75 0.68 0.69 0.68 0.69 0.69 0.97 0.98 1.01 1.23 1.28 1.28 1.35 1.47 — — —
Zoetis Inc. 1.77 1.82 2.13 2.30 2.31 2.30 2.51 2.55 2.67 2.70 2.84 2.78 3.00 2.58 2.93 3.08 3.29 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12).

1 Q4 2020 Calculation
Equity turnover = (RevenuesQ4 2020 + RevenuesQ3 2020 + RevenuesQ2 2020 + RevenuesQ1 2020) ÷ Total Pfizer Inc. shareholders’ equity
= (5,948 + 12,131 + 11,801 + 12,028) ÷ 63,238 = 0.66

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Pfizer Inc.’s equity turnover ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.